Objective: The objective of this study is to determine the potential effect of oral L-arginine supplementation on intestinal inflammation in very low birth weight (VLBW) neonates, as estimated by faecal calprotectin levels.
Introduction
Calprotectin is a 36.5-kDa calcium and zinc-binding protein that constitutes about 60% of all soluble cytosol proteins in human neutrophil granulocytes. 1 Its faecal measurement has been recognised as a reliable marker for the detection of gastrointestinal tract inflammatory activity in both children and adults. It can be a useful biomarker of gastrointestinal mucosa inflammation, and thus, of necrotising enterocolitis (NEC) in premature infants. [2] [3] [4] NEC is the most common acquired gastrointestinal disease in premature infants. In NEC, the small (most often distal) and/or large bowel becomes injured, develops intramural air, and this may progress to frank necrosis with perforation. 5 The high mortality and morbidity from NEC have not significantly improved during the last 40 years. 5, 6 Although extensive research has investigated the pathophysiology of NEC, a complete understanding has not been fully elucidated.
The pathology of NEC frequently resembles intestinal ischaemia reperfusion injury. An important regulator of vascular perfusion is endothelial nitric oxide (NO), an anti-inflammatory chemical mediator and vasodilator involved in the maintenance of mucosal integrity, intestinal barrier function and regulation of intestinal mucosal flow in the face of inflammation or injury. 7, 8 Inhibition of NO synthesis in a variety of animal models, in which bowel injury is induced, increases the area of intestinal damage. 7, 8 NO is synthetised from the amino acid L-arginine by NO synthases. Arginine is a 'conditionally' essential amino acid, meaning that endogenous arginine production covers metabolic requirements in healthy, unstressed individuals, but becomes an essential amino acid under conditions of increased need, for example, growth or tissue repair, or in catabolic states, such as sepsis and starvation. 9 In prematurely born human neonates, hypoargininaemia is frequently observed 10 and hypothesised to predispose such infants to the development of NEC. [11] [12] [13] A relative arginine deficiency or immaturity of NO synthases activity in premature infants may lead to deficient tissue NO levels, vasoconstriction and ischaemia reperfusion injury, and may predispose to NEC. Plasma arginine levels were found to be decreased in premature infants with NEC, [14] [15] [16] whereas other studies suggest that arginine supplementation can reduce the incidence of NEC. 17, 18 The aim of this double blind study was to determine whether arginine supplementation in very low birth weight (VLBW) neonates reduces gut inflammation, as assessed by faecal calprotectin concentrations.
Methods

Neonates
The present study enrolled 83 VLBW neonates with birth weight p1500 g and gestational age p34 weeks, as determined by the last maternal menstrual period and Ballard scoring system, 19 consecutively born in 'Alexandra' Hospital in Athens, Greece, between June 2009 and September 2010. Infants were excluded if they had lethal congenital or chromosomal abnormalities, inborn errors of metabolism, or if the parents did not give consent. The study protocol was approved by the Ethics Committee of the Hospital, and all parents signed informed consent before enrolment.
Study protocol
In this double-blind study, 83 VLBW neonates were prospectively randomly assigned either to receive a daily oral L-arginine supplement of 1.5 mmol kg À1 per day (261 mg kg À1 ) suspended in water for injection in two equal doses with oral feeds, from the 3rd to the 28th day after birth (N ¼ 40; arginine group), or placebo containing 5% glucose in equivalent volume (N ¼ 43; control group). The pharmacy prepared dilutions of the same volume of the oral arginine supplement and placebo containing 5% glucose, and the nurses giving the dilutions were not aware of the diluent constitute (not transparent bottles) and were blinded to the allocation of patients.
The dose of arginine was based on previous studies. 18 All babies were observed for side effects, such as diarrhoea, vomiting, low blood pressure and hypoglycaemia/hyperglycaemia.
Enteral feeds were commenced at 10 to 25 ml kg À1 per day on the first day of life (minimal feeding) and increased on the fourth day of life, and forward by 10 to 25 ml kg À1 per day as tolerated, up to a maximum of 150 to 180 ml kg À1 per day. Parenteral amino acids (Vamin 6.5%) was started on the first day of life at 1.5 g kg À1 per day and gradually increased to 3.5 g kg À1 per day. Vamin 6.5% contains 4.1 g of L-arginine per 1000 ml. Breast milk contains about 54 mg of L-arginine per 100 ml, 20 although the actual arginine content of own mother's milk was not measured. Breast milk was always fortified (Nutricia, Amsterdam, Netherlands) with two sachets of fortified breast milk/100 ml. Full-strength breast milk fortification (two sachets in 100 ml of milk) increases the concentration of L-arginine in the milk by 24 mg per 100 ml.
Thus, breast-fed infants received about 78 mg per 100 ml arginine from milk. Formula-fed infants received Almiron premature (Almiron premature, Numico, Amsterdam, Netherlands), which contains 82.6 mg L-arginine per 100 ml, a concentration in the recommended range of arginine in preterm formula. 21 No bank milk (donors' milk) was used.
Clinical data
Demographic data, fluid intake, total caloric intake, total arginine intake, total protein intake, weight and head growth were recorded. We used an electronic scale with accuracy of 10 g to weigh babies, a stadiometer to measure body length, and a non-stretchable tape to assess head circumference.
Faecal calprotectin levels Sample collection, sample preparation and analysis. Stool samples were collected from the neonates' diapers with sterile plastic spoons and put in sterile plastic screw-cap tubes at 3rd, 14th and 28th day after birth. All stool samples were stored at 4 1C, and faecal calprotectin levels were measured within 3 days using Calprotectin ELISA KIT (Bü hlmann Laboratories AG, Schönenbuch, Switzerland), according to the manufacturer's instructions. In detail, after the sample collection and a short extraction procedure (1 g stool sample: 4.9 ml extraction buffer), the extract was stored at À20 1C until the measurement of calprotectin. A sample dilution of 1:50 was applied for all samples, which gives accurate measurements for calprotectin values within the range of 10 to 600 mg g À1 (lower range procedure). For samples exceeding 600 mg g
À1
, a sample dilution of 1:150 was also applied, which gives more accurate measurements for calprotectin values within the range 600 to 1800 mg g À1 (extended range procedure). All controls and specimen was measured in duplicate.
Incidence of NEC in the first 3 months of life: diagnosis and classification of NEC. The diagnosis and classification of NEC was done according to modified Bells' criteria. [22] [23] [24] The neonatologists who classified the episodes of NEC, as well as the radiologist who evaluated the abdominal X-rays were blinded to the allocation of patients.
Sample size. We calculated that a sample size of 45 neonates in each group will have 80% power to detect a difference in means of 60 mg g À1 in calprotectin concentrations, assuming that the common s.d. between the two groups is 100, using a two group t-test with a 0.05 two-sided significance level. The study was not a priori powered to detect differences in NEC incidence.
Statistical analysis. Pearson's w 2 -test with continuity correction of Fisher's exact test were used to investigate the association between demographic/clinical data and the groups of interest (arginine vs control group). Day 3 values regarding faecal calprotectin, head growth and weight were tested between arginine and control group with independent sample t-test. Changes over time between arginine and control group were examined as in repeated-measures analysis mixed-effects model assigning a random intercept for each subject.
To reduce the sample variability, faecal calprotectin was transformed into the respective natural logarithmic scale. Sample descriptives regarding these variables are presented by geometric means. Significance level is set at 5%. Statistical package SAS V9.2 (SAS Institute, Cary, NC, USA) has been used for the data analysis.
Results
Between June 2009 and September 2010, 171 neonates of p34 and birth weight p1500 g were born in 'Alexandra' University In Table 2 , the incidence of common events occurring in preterm neonates is shown. No statistically significant differences between arginine and control groups were observed. Table 3 describes the incidence, morbidity and mortality associated with NEC in the two groups.
Neonates in both arginine and control group had a significant increase in weight and head circumference over time (P<0.0001). (Table 5 ). There was no statistically significant difference in the mean calprotectin values between the two groups on day 3, 14 and 28 (P ¼ 0.60, P ¼ 0.18 and P ¼ 0.72, respectively). Moreover, comparing the calprotectin values over time within the groups, we found that these values significantly decreased over time in both groups (P ¼ 0.032). This decrease over time was similar in both groups (P ¼ 0.554; Figure 1 ).
There were no differences in fluid or caloric intake between neonates receiving L-arginine supplementation and neonates All the values expressed as mean (95% conference interval). a Arginine group received 1.5 mmol kg À1 per day arginine supplementation. Faecal calprotectin in neonates receiving arginine E Polycarpou et al receiving placebo on days 3, 14 and 28. There is a significant difference in arginine intake due to arginine supplementation.
Discussion
In this randomised double-blind trial, our aim was to determine whether arginine supplementation leads to lower calprotectin values, indicating that neonates receiving arginine supplementation have a milder inflammatory response. Arginine supplementation was administered exclusively orally, considering that arginine could have beneficial effect locally on the intestinal mucosa itself, increasing proliferation and differentiation because of the production of other amino acids and polyamines. 9, 25 No adverse effects from oral arginine supplementation of 1.5 mmol kg À1 per day were noted. Considerably higher therapeutic doses of L-arginine have been used (loading 600 mg kg À1 followed by an infusion of 250 mg kg À1 per day) without adverse effects in the management of urea cycle disorders. 26, 27 The usefulness of faecal calprotectin as a marker of bowel inflammation remains controversial in the neonatal period because of high levels in this age range. The reference normal upper value for healthy adults and children ages from 4 to 17 years, regardless of sex, is 50 mg g À1 . 28 Several groups have reported that term and preterm infants have a wide range and higher average faecal calprotectin levels than healthy adults. [29] [30] [31] [32] [33] [34] Calprotectin values of 363 and 636 mg g À1 have been recommended as a cut-off for the detection of mild or severe enteropathy in preterm neonates, respectively. 31 A high average calprotectin value was found on day 3 (meconium before arginine supplementation) in both groups. This is consistent with previous studies measuring calprotectin levels in meconium in VLBW infants. 35 In agreement with others, 31, 33 we found that faecal calprotectin decreases with postnatal age. There was no significant difference comparing the mean calprotectin values in the arginine and control group on day 3, 14 and 28. Possible explanations of this could be that calprotectin is not a reliable biomarker for early diagnosis of bowel inflammation in neonates, or that arginine supplementation in the dose used has no effect on bowel inflammation. The target difference between the two groups set in this study was 60 mg g À1 . With a much larger sample, even a very small difference such the one found on day 28 (20 mg g À1 ), if it exists, could be proven to be statistically significant. We would recommend larger studies with different doses of arginine and/or longer duration of treatment.
Interestingly, the mean calprotectin value is lower on day 28 in breast-milk-fed neonates receiving arginine supplementation, comparing with neonates being fed with formula (with and without arginine supplementation) and neonates receiving breast milk without arginine supplementation, but not significantly (Table 5 ). There may be a synergistic preventive action of arginine with breast milk, and it would be interesting to investigate it in a larger study with babies receiving breast milk with or without arginine supplementation.
The incidence of NEC (stage II and III) in our study was found to be higher in the control group comparing with the arginine group (23.3% vs 10%, respectively), but this does not reach statistical significance. A sample size of minimum 122 neonates per group would be required to detect a reduction in the incidence of NEC from 23.3 to 10% with a two-sided 5% significance level and a power of 80%.
In conclusion, faecal calprotectin values decrease with increasing postnatal age in VLBW infants, but this does not seem to be related to arginine supplementation. Thus, either arginine has no influence on bowel inflammation in the dose used or faecal calprotectin is not a good biomarker for early stages of inflammation.
